Trial reportEuropean radiology experimental2026
Evaluation of the safety and efficacy of
Trial report in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveMetastatic castration-resistant prostate cancer (mCRPC) remains associated with poor long-term outcomes, and survival under current treatment is modest. Prostate-specific membrane antigen (PSMA)-targeted alpha therapy using MATERIALS AND
methodsThis prospective, open-label, single-arm study enrolled 16 patients with progressive mCRPC refractory to standard therapies. Patients received
resultsXerostomia occurred in 75% of patients, predominantly grade-1 (68.8%), with one grade-2 case. Hematologic toxicities were mild-to-moderate: anemia 68.8% (grade 3: 6.3%), leukopenia 25.0% (all grade 1-2). No grade 4 toxicities or treatment-related deaths occurred. Significant laboratory changes included hemoglobin decrease (117.7 ± 19.2 versus 105.0 ± 19.7 g/L, p = 0 .012). PSA50 response was 37.5% (95% confidence interval [CI]: 15.2%-64.6%), with a median PSA change of 18.1% (range: -143.0% to 100.0%). Radiographic response was 31.3% (95% CI: 11.0-58.7%), and the disease control (partial response + stable disease) rate was 62.5% (95% CI: 35.4-84.8%).
conclusionIn this first-in-human study of 16 patients, CLINICAL
trial registrationChinese Clinical Trial Registry: ChiCTR2400083275, Registered 19 April 2024. https://www.chictr.org.cn . KEY POINTS: Question What are the safety and efficacy outcomes of the novel alpha-emitting radiopharmaceutical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.